Xtant Medical (XTNT) to Release Quarterly Earnings on Thursday

Xtant Medical (NYSEAMERICAN:XTNT - Get Free Report) is expected to issue its quarterly earnings data after the market closes on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $31.80 million for the quarter. Parties interested in registering for the company's conference call can do so using this link.

Xtant Medical Price Performance

Shares of XTNT traded down $0.02 during trading hours on Friday, hitting $0.46. The company's stock had a trading volume of 23,592 shares, compared to its average volume of 95,643. Xtant Medical has a 52-week low of $0.33 and a 52-week high of $1.24. The company has a 50 day moving average price of $0.52. The company has a current ratio of 2.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.42. The company has a market cap of $64.11 million, a P/E ratio of -3.55 and a beta of 0.35.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.